33 results about "Vaccine evaluation" patented technology

A competitive enzyme-linked immunosorbent assay (C-ELISA), using flavivirus member specific immunological agents was developed to detect antibody specific to members of the flaviviruses indicative of exposure to flavivirus. The test is based on a competition for epitope binding on the envelope protein of the flavivirus antigen captured using anti-flavivirus IgA in the presence of flavivirus positive serum. This test has comparable sensitivity specificity and speed to the virus neutralization assay (VNT). C-ELISA is a versatile technique, which could have various applications. Slight modifications of this protocol could lead to a C-ELISA-based detection method of secondary infection or one that could be used for serotype specific sero-epidemiological studies and / or vaccine evaluation. The protocol developed for C-ELISA was demonstrated using dengue lysate antigen and dengue specific monoclonal antibody. This can be used against other flaviviruses and the results for Japanese encephalitis illustrates this.

The invention discloses a recombinant influenza virus and application thereof and provides a preparation method of the recombinant virus. The preparation method comprises the following steps: guiding an HA6 subtype influenza virus hemagglutinin encoding gene, an influenza virus neuraminidase (NA) gene and six genes including PB2, PB1, PA, NP, M and NS in an influenza virus into a host cell together, and packing to obtain the recombinant virus. The invention also discloses a detection method for detecting antibodies for inhibiting activities of seasonal influenza N1, N2, 2009H1N1N1 and 2013H7N9N9 enzymes by virtue of the recombinant virus. The detection method comprises the steps of sample treatment and result analysis. According to the invention, the immune response to NA of people can be rapidly and effectively measured, the operation is simple, the application is convenient, and viable technical support is provided for clinical detection and vaccine evaluation.

The invention relates to the field of a virus, a compound and preparation or purification of the virus, in particular to a chimeric virus of a complete envelope protein of an HCV (hepatitis C virus) and a GB virus B. The chimeric virus is formed by sequentially connecting a 5'-end non-coding region and core protein gene sequence of the GB virus B, a complete envelope protein gene sequence of the HCV and a nonstructural protein and 3'-end non-coding region sequence of the GB virus B, wherein the complete envelope protein gene sequence of the HCV is a complete envelope protein gene sequence of a 1b-genotype HCV. A marmoset monkey can be successfully infected by the virus by carrying out intrahepatic injection and intravenous injection of a primary marmoset monkey serum containing the chimeric virus. The chimeric virus simulates infection and immune states of the HCV in a primate body. A platform for carrying out immunoassay and evaluation on the complete envelope protein of the HCV is provided. The scientific problems of limitation on HCV immunity prevention and treatment research, vaccine evaluation and the like due to shortage of a small primate infection model are solved.

The invention relates to a virus challenge method for rainbow trout vaccine evaluation, belonging to the technical field of aquatic product challenge methods. In order to solve the problems that the existing rainbow trout vaccine evaluation and challenge method is inconvenient to operate and the parallelism of the challenge effect is poor, the present invention provides a challenge method for rainbow trout vaccine evaluation. The body length and body height were measured on the operation platform of the challenge experiment, the body width was measured after the dorsal fins of the rainbow trout were fixed upward, and the depth of the syringe needle was determined according to the body size of the rainbow trout. After the rainbow trout is awake in the fish body awakening pond, it swims back to the fish body culture pond by itself through the entry conduit. The invention quickly, efficiently, safely and stably completes the operations of fish body anesthesia, challenge and recovery in the rainbow trout challenge experiment platform system, without the need for round-trip transportation, saving time and effort, and not only ensuring the safety of the fish body, but also ensuring the attack experiment. parallelism.

The microfluidic platform device of the claimed invention makes use of a high throughput lab-on-a-chip format to determine the functional profile of antibodies elicited by infection or vaccination against infection for any pathogen. It can be used to evaluate vaccines, evaluate whether vaccinated individuals show indices of protection, determine whether individuals display resistance or susceptibility to infection, discover new vaccine antigens, discover and test therapeutic interventions, or evaluate mechanisms of disease.

The invention discloses a Japanese encephalitis virus (JEV) infectious clone with a luciferase gene, and a building method and application thereof. The JEV infectious clone with the luciferase gene is prepared by the following steps: (1) sectional synthesis of a JEV SA14 strain gene sequence; (2) assembling and building of the JEV infectious clone; (3) building of the JEV infectious clone with the luciferase gene. It is proved that a Rluc-JEV report virus with the same growth tendency as the JEV virus can be saved by the JEV infectious clone with the luciferase gene built by the method, and the JEV infectious clone has wide application value in the aspects of an animal model, virus replication and pathogenesis, drug screening and drug action mechanism, live animal imaging and vaccine evaluation and the like through the experiments of immunofluorescence, Rluc activity detection, virus bacteriophage plaque, drug inhibition, live animal imaging, vaccine evaluation and the like.

The invention discloses an enhanced green fluorescent protein recombinant H5N1 subtype influenza virus and its application. The genome of the recombinant H5N1 subtype influenza virus is composed of eight RNA fragments of the following a) and b): a) seven RNA fragments which are same as the genome of wild type H5N1 subtype influenza virus contains RNA fragment 1 encoding PB2 protein, RNA fragment 2 encoding PB1 and PB1-F2 proteins, RNA fragment 3 encoding PA protein, RNA fragment 4 encoding HA protein, RNA fragment 5 encoding NP protein, RNA fragment 7 encoding M1 and M2 proteins, RNA fragment 8 encoding NS1 and NS2 proteins; b) fragment 6' which is obtained by the insertion of RNA fragment containing green fluorescent protein coding RNA to 5'-noncoding region of RNA fragment 6 encoding NA protein in the genome of wild type H5N1 subtype influenza virus. According to the invention, rapid quantitative determination of the recombinant virus can be performed by observation of fluorescence positive cell number and fluorescence intensity, cumbersome procedure of regular titration is saved, and a convenient and effective tool for anti-H5N1 subtype influenza virus drug screening and vaccine evaluation is provided.